Inflammatory Response After Muscle and Skeleton Trauma (IRAMST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00710411
Recruitment Status : Completed
First Posted : July 4, 2008
Last Update Posted : December 17, 2015
German Research Foundation
Information provided by (Responsible Party):
Manfred Weiss, University of Ulm

Brief Summary:
The purpose of this study is to determine the inflammatory response after multiple trauma in humans.

Condition or disease
Multiple Trauma

Detailed Description:
Polytraumatized patients are via a systemic inflammatory response syndrome at high risk for an uneventful outcome in the posttraumatic phase. One of the main functions of the inflammatory response is the recognition and elimination of damaged tissues and microorganisms. In polytraumatized patients, a huge amount of damaged cells occurs which has to be eliminated by programmed cell death (apoptosis)without damaging surrounding tissues. It remains unclear whether, when and how an interplay of complement system, NF-kB, danger and pattern recognition receptors, apoptosis, mesenchymal stem cells and their regulation may be beneficial and harmful. Differing activation of the complement system, pro-inflammatory biomarkers and predisposing polymorphisms of response and receptor genes are expected to lead to varying outcome. Therefore, this prospective observational study will enroll n=60 polytraumatized patients with an ISS>18 to monitor longitudinally their inflammatory response after trauma and to find out whether there is a discriminating pattern of the cross talk between complement system, biomarkers and apoptosis in patients with beneficial or harmful outcome.

Study Type : Observational
Actual Enrollment : 48 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Inflammatory Response in Polytraumatized Patients
Study Start Date : April 2009
Actual Primary Completion Date : October 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

A, 2
Polytraumatized patients with ISS > 18 and healthy controls

Primary Outcome Measures :
  1. Inflammatory pattern of complement activation, biomarkers and complement-regulating proteins (CRegs)on leukocytes [ Time Frame: 0, 1, 4, 12, 24, 48, 96, 120 und 240 h after trauma ]

Secondary Outcome Measures :
  1. inflammatory biomarkers, cell surface markers, apoptosis, functional polymorphisms, mesenchymal stem cells, severity of injury (ISS), infections, SIRS, sepsis, shock, organ dysfunctions, severity of disease, ICU length of stay, wound healing, mortality [ Time Frame: 0, 1, 4, 12, 24, 48, 96, 120 und 240 h after trauma for biochemical and immunological parameters; ISS on admission; scores on a daily basis; ICU and hospital death on discharge ]

Biospecimen Retention:   Samples With DNA
Whole blood, serum, white cells, and tissues will be retained.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Polytraumatized patients with an ISS > 18 Controls: healthy volunteers

Inclusion Criteria:

  • multiple trauma injury, injury severity score (ISS) > 18 with

    1. isolated fractures of the extremities
    2. fractures of the extremities combined with blunt/penetrating visceral trauma
    3. fractures of the extremities combined with blunt/penetrating thoracic trauma
    4. isolated head injury with morphological changes in CCT
    5. combination of points 1 - 4

      Exclusion Criteria:

  • life expectancy < 24 hours
  • participation in other trials
  • ISS < 18
  • cardiopulmonary reanimation on the accident scene or dying immediately after hospital admission
  • age < 18 years
  • known or suspected pregnancy
  • patients with ray-treatment or chemotherapy within the last three months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00710411

Clinic of Anesthesiology and Clinic of Traumatology, Hand-, Plastic-, and Reconstructive Surgery
Ulm, Germany, 89070
Sponsors and Collaborators
University of Ulm
German Research Foundation
Principal Investigator: Manfred M Weiss, MD, MBA Clinic of Anesthesiology, University Hospital Medical School, Steinhoevelstrasse 9, 89070 Ulm, Germany

Publications of Results:
Responsible Party: Manfred Weiss, Professor, MD, MBA, University of Ulm Identifier: NCT00710411     History of Changes
Other Study ID Numbers: DFG KFO-200
First Posted: July 4, 2008    Key Record Dates
Last Update Posted: December 17, 2015
Last Verified: December 2015

Keywords provided by Manfred Weiss, University of Ulm:
inflammatory response
cell surface markers
functional polymorphisms
mesenchymal stem cell
severity of injury
systemic inflammatory response syndrome
severe sepsis
organ dysfunctions
severity of disease
length of stay
wound healing

Additional relevant MeSH terms:
Multiple Trauma
Wounds and Injuries